Healthcare R&D
Our research scientists are working tirelessly to develop groundbreaking medicines and technologies to treat everything from cancer and multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more
Life Science R&D
R&D focus: Reimagining new ways to meet the needs of our customers
Innovation is at the core of the value that we deliver to our customers. Our Life Science scientists and engineers tirelessly work to develop novel approaches to new and age-old challenges.We show our commitment to innovation through our financial investments as well. Every year, we invest around €400 million in R&D, supporting new innovations designed to meet our customers' most unmet needs – from antibodies to water purification systems. Innovation is visible when new products hit the shelves and when new services emerge.
The ability to innovate is the core of our culture across all three of our businesses; Science & Lab Solutions, Process Solutions and Life Science Services. Learn more
Electronics R&D
R&D focus: Keeping the world’s Electronics on the cutting edge
Our Electronics business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more
Related News
View All News-
Press Releases
Launch of EdiMembre to Transform Alternative Protein Industry
Together with mantro GmbH we have established EdiMembre, Inc., Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry.
2025/08/18
-
Press Releases
European Commission Grants Approval of Ogsiveo
The European Commission granted approval for Ogsiveo for the treatment of adults with desmoid tumors.
2025/08/18
-
Press Releases
European Commission Grants Conditional Approval of EZMEKLY
The European Commission granted approval for EZMEKLY for the treatment of adult and pediatric patients with NF1-PN.
2025/07/18